Home › Non-Small Cell Lung Cancer › North Carolina › Winston-Salem
Non-Small Cell Lung Cancer clinical trials in Winston-Salem, NC
12 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Winston-Salem (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
- Wake Forest University Health Sciences, Winston-Salem
- Wake Forest University at Clemmons, Clemmons · 9 mi away
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RecruitingPhase 3
- Novant Health Forsyth Medical Center ( Site 0166), Winston-Salem
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
RecruitingPhase 3
- Novant Health Pharmacy Oncology Specialists, Winston-Salem
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
RecruitingPhase 3
- Novant Health Pharmacy Oncology Specialists, Winston-Salem
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
RecruitingPhase 2
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
RecruitingPhase 2
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
RecruitingPhase 3
- Atrium Health Wake Forest Baptist, Winston-Salem
Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study
RecruitingObservational study
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RecruitingPhase 2
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecruitingObservational study
- Wake Forest NCORP Research Base, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
- Wake Forest University at Clemmons, Clemmons · 9 mi away
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Winston-Salem
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Other studies in Winston-Salem
- Cancer (all types)19 studies
- Acute Myeloid Leukemia18 studies
- Multiple Myeloma14 studies
- Breast Cancer14 studies
- Cardiovascular Disease14 studies
- COPD10 studies
- Ovarian Cancer10 studies
- Type 2 Diabetes9 studies
- Myelodysplastic Syndromes9 studies
- Glioblastoma8 studies
- Chronic Lymphocytic Leukemia8 studies
- Lung Cancer8 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.